John B Porter

A phase 2 study of the safety, tolerability, and pharmacodynamics of FBS0701, a novel oral iron chelator, in transfusional iron overload.

Vip Viprakasit, Hugh Young Rienhoff, Paul Harmatz, 2012, Blood.

Iron overload in thalassemia and related conditions: therapeutic goals and assessment of response to chelation therapies.

Farrukh T Shah, John B Porter, J. Porter, 2010, Hematology/oncology clinics of North America.

On T2* Magnetic Resonance and Cardiac Iron

Dudley J Pennell, David N Firmin, Paul Kirk, 2011, Circulation.

Biopsy-based calibration of T2* magnetic resonance for estimation of liver iron concentration and comparison with R2 Ferriscan

Dudley J Pennell, Taigang He, John-Paul Carpenter, 2014, Journal of Cardiovascular Magnetic Resonance.

Deferasirox demonstrates a dose-dependent reduction in liver iron concentration and consistent efficacy across subgroups of non-transfusion-dependent thalassemia patients

Vip Viprakasit, Ali T Taher, Dany Habr, 2013, American journal of hematology.